Overview
CRIS market data
Price History
CRIS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$11.52 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.36 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -80.3% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $1.63 – $39.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $3.3M · P/B 2.34 · P/S 0.34.
Company News
12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga · Aug 11, 2026, 5:06 PM
Curis Announces First Five Patients Dosed In TakeAim CLL Study Of Emavusertib With Zanubrutinib; Reaffirms Initial Data In 5-10 Patients In December 2026Benzinga · Jul 30, 2026, 12:10 PM
Curis Gains As Blood Cancer Drug Progresses, December Readout in FocusBenzinga · Jul 24, 2026, 6:03 PM
Curis shares are trading higher after HC Wainwright & Co. maintained its Buy rating on the stock and raised its price target from $17 to $43.Benzinga · Jul 24, 2026, 3:21 PM
HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43Benzinga · Jul 24, 2026, 10:14 AM
Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response RatesBenzinga · Jul 22, 2026, 5:04 PM
Curis To Announce Positive Updates On Emavusertib Studies For Lymphoma And Lymphociytic Leukemia July 22Benzinga · Jul 22, 2026, 11:12 AM
Why Q32 Bio Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 13, 2026, 8:39 AM
Curis Announces It Has Consented The First Six Patients In The TakeAim CLL StudyBenzinga · Jul 6, 2026, 1:35 PM
8-K filing — CURIS INC (CRIS)SEC EDGAR · Jul 2, 2026, 12:56 PM